← Back to Search

Quit2Heal App for Smoking Cessation in Cancer Patients

Phase 3

Recruiting

Led By Jonathan Bricker

Research Sponsored by Fred Hutchinson Cancer Research Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age 18 or older

Diagnosed with cancer within the past 24 months or currently receiving or planning to receive cancer treatment in the next 3 months

Timeline

Screening 3 weeks

Treatment Varies

Follow Up at 3 months after randomization

Awards & highlights

Study Summary

This trial is testing whether the Quit2Heal app is more effective than the QuitGuide app in helping cancer patients quit smoking.

Who is the study for?

This trial is for adults over 18 in the US who have been diagnosed with cancer within the last two years or are undergoing treatment. Participants must be current smokers interested in quitting, willing to use a smartphone app for cessation, and able to complete surveys. They should not be using other quit-smoking programs or have used NCI's QuitGuide app.Check my eligibility

What is being tested?

The study compares two smoking cessation apps: Quit2Heal and QuitGuide. Both offer strategies to handle cravings, guides on quitting, staying smoke-free plans, and advice on choosing medications that help stop smoking. Patients will randomly receive one of these apps.See study design

What are the potential side effects?

Since this trial involves the use of smartphone applications rather than medication, there are no direct medical side effects associated with participation. However, participants may experience stress or frustration related to quitting smoking.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

I was diagnosed with cancer in the last 2 years or will start treatment soon.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ at 3 months after randomization

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~at 3 months after randomization

This trial's timeline: 3 weeks for screening, Varies for treatment, and at 3 months after randomization for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of participants with 30-day cigarette smoking cessation at 12 months.

Secondary outcome measures

Number of participants with 30-day cigarette smoking cessation at 3 months.

Number of participants with 30-day cigarette smoking cessation at 6 months.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Arm I (Quit2Heal app)Experimental Treatment2 Interventions

Patients receive the Quit2Heal app and are encouraged to use it frequently. During the entire 12-month follow-up period, the app will remain fully available anytime study participants wish to use it.

Group II: Arm II (QuitGuide app)Active Control2 Interventions

Patients receive the QuitGuide app and are encouraged to use it frequently. During the entire 12-month follow-up period, the app will remain fully available anytime study participants wish to use it.

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Fred Hutchinson Cancer Research CenterLead Sponsor

443 Previous Clinical Trials

147,950 Total Patients Enrolled

Fred Hutchinson Cancer CenterLead Sponsor

556 Previous Clinical Trials

1,342,973 Total Patients Enrolled

National Cancer Institute (NCI)NIH

13,665 Previous Clinical Trials

40,925,432 Total Patients Enrolled

1 Trials studying Blood Cancers

70 Patients Enrolled for Blood Cancers

Media Library

Quit2Heal Smartphone App Clinical Trial Eligibility Overview. Trial Name: NCT04409236 — Phase 3

Blood Cancers Research Study Groups: Arm I (Quit2Heal app), Arm II (QuitGuide app)

Blood Cancers Clinical Trial 2023: Quit2Heal Smartphone App Highlights & Side Effects. Trial Name: NCT04409236 — Phase 3

Quit2Heal Smartphone App 2023 Treatment Timeline for Medical Study. Trial Name: NCT04409236 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the risks associated with the Quit2Heal treatment program?

"Our analysts have rated Quit2Heal as a 3 in terms of safety. This is due to the fact that this is a Phase 3 trial, meaning that there is evidence of the medication's efficacy and repeated data sets affirming its safety."

Answered by AI

Is there still room for more study participants?

"The trial, which was created on 7/19/2021 and last updated 9/20/2022, is currently seeking participants, as is evident from the clinicaltrials.gov posting."

Answered by AI